BRNS

Barinthus Biotherapeutics
BRNS

Overview Fund Activity

15 hedge funds and large institutions have $22.2M invested in Barinthus Biotherapeutics in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
15
Holders Change
+4
Holders Change %
+36.36%
% of All Funds
0.24%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
4
Increased
1
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Baird Financial Group
Baird Financial Group
Wisconsin
+$217K
2
Citadel Advisors
Citadel Advisors
Florida
+$41.5K
3
TSS
Two Sigma Securities
New York
+$39.8K
4
Millennium Management
Millennium Management
New York
+$23.9K

Top Sellers

1
IIM
Ipswich Investment Management
Massachusetts
-$4.94K
2
UBS Group
UBS Group
Switzerland
-$3.38K
3
Morgan Stanley
Morgan Stanley
New York
-$1.77K
Name Holding Trade Value Shares
Change 		Shares
Change %
MGIM
1
M&G Investment Management
United Kingdom
$10.4M – – –
AI
2
Alphabet Inc
California
$3.56M – – –
HH
3
HSG Holding
Hong Kong
$3.34M – – –
DF
4
DC Funds
Virginia
$1.51M – – –
LIP
5
Liontrust Investment Partners
United Kingdom
$1.43M – – –
BCM
6
BlueCrest Capital Management
Jersey
$1.28M – – –
JHU
7
Johns Hopkins University
Maryland
$254K – – –
Baird Financial Group
8
Baird Financial Group
Wisconsin
$217K +$217K +92,461 New
Millennium Management
9
Millennium Management
New York
$97K +$23.9K +9,967 +33%
IIM
10
Ipswich Investment Management
Massachusetts
$50.2K -$4.94K -2,100 -9%
Citadel Advisors
11
Citadel Advisors
Florida
$41.5K +$41.5K +17,383 New
TSS
12
Two Sigma Securities
New York
$39.8K +$39.8K +16,919 New
Morgan Stanley
13
Morgan Stanley
New York
$27.8K -$1.77K -753 -6%
UBS Group
14
UBS Group
Switzerland
$8.82K -$3.38K -1,437 -28%
NECFA
15
New England Capital Financial Advisors
Connecticut
$282 +$282 +104 New